Compare Enveric Biosciences Inc (ENVB) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Rigetti Computing Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Rigetti Computing Inc trades at $14.03 (market cap $4.72B). The key difference: Rigetti Computing Inc is far larger — about 694.1× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 17,136,381). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Rigetti Computing Inc for 35 Days on average.
| ENVB | RGTI | |
|---|---|---|
Market Cap | $6.80M | $4.72B |
Volume | 64,867 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $10.80 | $56.34 |
52-Week Low | $1.27 | $12.90 |
Typical Hold Time | 14 Days | 35 Days |
Enterprise Value | -$1.49M | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
RGTI trades at $13.89, down 4.8% in the last session, amid bearish technical signals but strong analyst support. The company shows minimal revenue of $7.09M (2025) with significant losses (-$216.21M net income), though recent quarters saw mixed earnings beats. Positive sentiment stems from quantum computing sector momentum and strategic partnerships, yet high valuation ratios (P/S 349.79) and negative cash flow pose challenges.
Outlook: Analyst consensus is bullish (85.7% buy ratings) with a $21.67 price target, suggesting 56% upside, but high execution risks and cash burn require caution. Investment opportunity hinges on commercial scaling of quantum technology, while risks include sustained losses and competitive pressure in the emerging quantum sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
